• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Opinion
Video

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      4 experts are featured in this series.
      Diagnosing IgA Nephropathy
      A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
      A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
      1 expert is featured in this series.
      AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics
      How the Genetic Nature of Lp(a) Levels Influences Screening
      How the Genetic Nature of Lp(a) Levels Influences Screening
      4 experts are featured in this series.
      Pathogenesis of IgA Nephropathy: The 4-Hit Cascade, A Proliferation-Inducing Ligand (APRIL), and cytokines
      3 experts are featured in this series.
      Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?
      3 experts are featured in this series.
      Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities
      3 experts are featured in this series.
      Emerging Therapeutic Areas for Bispecific Antibodies
      3 experts are featured in this series.
      Payer and Reimbursement Considerations for Bispecific Therapies
      3 experts are featured in this series.
      Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration
      Related Content
      Site Logo

      A Population Health Approach to Managing Heart Failure

      September 23rd 2022
      Article

      Read More

      © 2025 MJH Life Sciences
      AJMC®
      All rights reserved.